Comparison of risk of serious infections between patients treated with tumor necrosis factor-α (TNFα) antagonists and those treated with vedolizumab: A retrospective cohort study
Latest Information Update: 01 Mar 2022
At a glance
- Drugs Vedolizumab (Primary) ; Tumour necrosis factor alpha inhibitors
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- 22 Dec 2020 New trial record
- 28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020